- Director, the Pharmacogenomics of Anticancer Agents Research (PAAR) Cell Line Core
- Assistant Professor, Department of Medicine, Cancer Research Center, Center for Personalized Therapeutics, Committee on Clinical Pharmacology and Phamacogenomics, Committee on Cancer Biology
M.S. and Ph.D., Department of Pharmacy Practice, Purdue University, 2005
The University of Chicago
900 East. 57th Street
Chicago, Illinois 60637
Phone: (773) 702-9363
Translational Pharmacogenomic Research with Particular Interest in the Pharmacogenomics of Anticancer Agents
My lab research focuses on translational pharmacogenomic research with particular interest in the pharmacogenomics of anticancer agents. By systematically evaluating the human genomes and their relationships to drug response and toxicity, our goal is to develop clinically useful models that predict risks for adverse drug reactions and non-response prior to administration of chemotherapy. We utilize cell lines (derived from healthy and disease individuals as well as commercially available cancer cell lines), and clinical samples to discover and functional characterize genetic variations, gene and microRNA (miRNA) expression for their role in chemotherapeutic sensitivity.
Non-cytotoxic anti-cancer agent pharmacogenomics
- Develop cellular phenotyping assays for non-cytotoxic anti-cancer agents. Current drugs of interest include glucocortocoids, tamoxifen, HDAC inhibitors;
- Perform genome-wide multi-dimensional integrative analysis to identify genetic variants (in the form of SNP or CNV) that are associated with drug sensitivity through their effect on miRNA and/or gene expression;
- Clinical replication of identified markers.
- Mechanistic study of genome-wide association study findings for cytotoxic agents and clinical validation ;
Utilizing lymphoblastoid cell lines, various cancer cell lines and clinical samples, we perform overexpression and inhibition experiments to examine the gene/miRNA function in drug sensitivity.
- Novel drug sensitivity model development
We are currently working on develop drug sensitivity prediction models using various human biological speciments.